Breathe Well Live Well
|
Novel gene therapy shows potential for lung repair in asthma
Science Daily In asthma, airways become inflamed, resulting in narrowing of these airways and debilitating symptoms that include coughing, wheezing, shortness of breath and chest tightness. Asthma and other respiratory diseases also cause changes in the large and … |
View full post on asthma – Google News
EurekAlert (press release) |
Novel gene therapy shows potential for lung repair in asthma American Thoracic Society
EurekAlert (press release) ATS 2016, SAN FRANCISCO — A new study has demonstrated a way to deliver a nanoparticle-based gene therapy, in order to repair lungs damaged by chronic allergic asthma and to reduce inflammation that causes asthma attacks. The potential therapy … |
View full post on asthma – Google News
HealthCanal.com (press release) (blog) |
New mobile app has the potential to revolutionise asthma management
HealthCanal.com (press release) (blog) The MASTERY program, supported by the Monash Research Impact Fund, can help pregnant women monitor their asthma regularly, effectively and in partnership with their primary healthcare providers. The MASTERY telehealth program, involves the use of … |
View full post on asthma – Google News
Lung Disease News |
Potential Target for Severe Asthma, Other Chronic Inflammatory Diseases Identified
Lung Disease News From previous research it was known that Dkk-1, a protein produced by platelets (blood cells responsible for clotting), inhibits tissue repair, a feature that is common in chronic inflammatory disorders such as asthma, autoimmune diseases and cancer … |
View full post on asthma – Google News
|
GSK's First Biologic Treatment For Asthma – Nucala Holds Multi-Billion Dollar Potential
Seeking Alpha Nucala was recently approved by the USFDA and EMA for the treatment of patients with severe Asthma of eosinophilic phenotype. In the base case, Nucala should reach peak sales of $2b. If Nucala is approved in other indications (COPD, HES) too, it can … |
View full post on asthma – Google News
ChristianToday |
Asthma drug a potential treatment for aging brains, according to new study
ChristianToday A new study has found that a drug originally intended for the management of asthma attacks has been found to rejuvenate the aging brain. The study, conducted by researchers at Paracelsus Medical University in Austria and published in Nature … Affordable asthma medicine to treat dementia |
View full post on asthma – Google News
Lung Disease News |
Potential Asthma Drug OATD-01 Selected as First OncoArendi Therapeutics …
Lung Disease News AMCases are present in the human genome and have been found to be over-expressed and play a role in the Th2-specific and interleukin-13 –mediated pathway in pulmonary epithelial cells in human asthma. Neutralization of AMCase has been shown to … |
View full post on asthma – Google News
| Related Articles |
Therapeutic potential of soluble guanylate cyclase modulators in neonatal chronic lung disease.
Am J Physiol Lung Cell Mol Physiol. 2015 Oct 2;:ajplung.00333.2015
Authors: Wagenaar GT, Hiemstra PS, Gosens R
Abstract
Supplemental oxygen after premature birth results in aberrant airway, alveolar and pulmonary vascular development with an increased risk for bronchopulmonary dysplasia (BPD), and development of wheeze and asthma, pulmonary hypertension and COPD in survivors. Although stimulation of the nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic GMP (cGMP) signal transduction pathway has significant beneficial effects on disease development in animal models, so far this could not be translated to the clinic. Oxidative stress reduces the NO-sGC-cGMP pathway by oxidizing heme-bound sGC, resulting in inactivation or degradation of sGC. Reduced sGC activity and/or expression is associated with pathology due to premature birth, oxidative stress-induced lung injury, including impaired alveolar maturation, smooth muscle cell (SMC) proliferation and contraction, impaired airway relaxation and vasodilation, inflammation, pulmonary hypertension, right ventricular hypertrophy and an aggravated response towards hyperoxia-induced neonatal lung injury. Recently, Britt et al. (10) demonstrated that histamine-induced Ca2+ responses were significantly elevated in hyperoxia-exposed fetal human airway SMC’s compared to normoxic controls, and that this hyperoxia-induced increase in the response was strongly reduced by NO-independent stimulation and activation of sGC. These recent studies highlight the therapeutic potential of sGC modulators in the treatment of preterm infants for respiratory distress with supplemental oxygen. Such treatment is aimed at improving aberrant alveolar and vascular development of the neonatal lung, and preventing the development of wheezing and asthma in survivors of premature birth. In addition, these studies highlight the suitability of fetal human airway SMC’s as a translational model for pathological airway changes in the neonate.
PMID: 26432873 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
iDigitalTimes.com |
Scientists Discover Ineffective Osteoporosis Treatment Drug as a Potential …
iDigitalTimes.com Asthma patients can finally breathe more easily. A group of international scientists conducting a joint research in Wales and London recently discovered how a former bone drug used to treat osteoporosis can be a potential asthma treatment. Calcilytics … |
View full post on asthma – Google News
|
Calcium Sensing Receptor: Asthma's Potential Root Cause And A Novel Treatment
Science 2.0 Researchers have described the role of the calcium sensing receptor (CaSR) in causing asthma, a disease which affects 300 million people worldwide, by using mouse models of asthma and human airway tissue from asthmatic and non-asthmatic people. New asthma therapy? Approved drugs show promise New Study Claims Asthma Could Be Cured In Five Years Possible cause for some cases of asthma discovered |
View full post on asthma – Google News